This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision

1 week ago 14

Jonathan Ponciano, The Motley Fool

Fri, March 13, 2026 astatine 9:56 AM CDT 4 min read

Deerfield Management Company disclosed a bargain of 418,538 shares of Vera Therapeutics (NASDAQ:VERA) successful its February 17, 2026, SEC filing, with an estimated transaction worth of $14.87 cardinal based connected the quarter’s mean price.

According to a recent SEC filing, Deerfield Management Company accrued its holding successful Vera Therapeutics (NASDAQ:VERA) by 418,538 shares during the 4th fourth of 2025. The estimated transaction value, calculated utilizing the period’s mean closing price, was astir $14.87 million. The quarter-end worth of the involvement accrued by $99.77 million, reflecting some the further shares purchased and changes successful the banal terms during the period.

This was a buy, lifting the involvement to astir 2.6% of the fund’s 13F AUM
Top 5 holdings aft the filing:
- NASDAQ: NUVL: $1.74 cardinal (25.4% of AUM)
- NASDAQ: COGT: $321.24 cardinal (4.7% of AUM)
- NASDAQ: PRAX: $266.25 cardinal (3.9% of AUM)
- NYSE: CNC: $265.34 cardinal (3.9% of AUM)
- NASDAQ: VTRS: $251.57 cardinal (3.7% of AUM)
As of February 17, 2026, VERA shares were priced astatine $42.85, up astir 50% implicit the past year, compared to a 19% summation successful the S&P 500.

Metric

Value

Price (as of marketplace adjacent 2/17/26)	$42.85
Market capitalization	$3.00 billion
One-year terms change	50%

Vera’s pb merchandise campaigner is atacicept, a fusion macromolecule successful Phase IIb objective trials for immunoglobulin A nephropathy; besides processing MAU868, a monoclonal antibody successful Phase 2 for BK viremia infections.
The steadfast operates arsenic a clinical-stage biotechnology institution focused connected processing and commercializing caller therapeutics targeting superior immunological diseases.
It serves patients with superior immunological conditions, with a superior absorption connected the United States healthcare and biotechnology markets.

Vera Therapeutics, Inc. is simply a clinical-stage biotechnology institution headquartered successful Brisbane, California. The institution differentiates itself done the improvement of innovative biologic therapies targeting unmet needs successful immunological diseases, leveraging precocious macromolecule and antibody platforms. With a robust pipeline and absorption connected high-burden indications, Vera Therapeutics is positioned to code important gaps successful existent attraction options for uncommon and superior conditions.

Vera’s flagship cause candidate, atacicept, targets 2 proteins known arsenic BAFF and APRIL that thrust the accumulation of autoantibodies linked to respective kidney and autoimmune diseases, and objective advancement has pushed the programme to the regulatory stage. The FDA has granted precedence reappraisal for the biologics licence exertion for atacicept successful IgA nephropathy and acceptable a determination day of July 7, 2026, with a imaginable commercialized motorboat expected successful the mediate of this year. The exertion follows affirmative Phase 3 information from the ORIGIN survey program, which demonstrated meaningful reductions successful proteinuria and stabilization of kidney function.

Financially, Vera is positioned to scope that milestone. The institution ended 2025 with astir $714.6 cardinal successful cash, currency equivalents, and marketable securities, which absorption says should supply backing done a imaginable support and U.S. launch.

For semipermanent investors, this upcoming regulatory determination represents the inflection constituent that could displacement Vera from a clinical-stage biotech into a commercialized immunology player, truthful the adjacent fewer months volition beryllium crucial.

Read Entire Article